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Monoclonal gammopathy of undetermined significance is a pre-malignant precursor of multiple myeloma with a 1% risk ofprogression per year. Although targeted analyses have shown
the presence of specific genetic abnormalities such as IGH translocations,
RB1 deletion, 1q gain, hyperdiploidy or RAS gene mutations, little is
known about the molecular mechanism of malignant transformation.
We performed whole exome sequencing together with comparative
genomic hybridization plus single nucleotide polymorphism array analy-
sis in 33 flow-cytometry-separated abnormal plasma cell samples from
patients with monoclonal gammopathy of undetermined significance to
describe somatic gene mutations and chromosome changes at the
genome-wide level. Non-synonymous mutations and copy-number
alterations were present in 97.0% and in 60.6% of cases, respectively.
Importantly, the number of somatic mutations was significantly lower in
monoclonal gammopathy of undetermined significance than in myelo-
ma (P<10-4) and we identified six genes that were significantly mutated
in myeloma (KRAS, NRAS, DIS3, HIST1H1E, EGR1 and LTB) within the
monoclonal gammopathy of undetermined significance dataset. We also
found a positive correlation with increasing chromosome changes and
somatic gene mutations. IGH translocations, comprising t(4;14), t(11;14),
t(14;16) and t(14;20), were present in 27.3% of cases and in a similar fre-
quency to myeloma, consistent with the primary lesion hypothesis.
MYC translocations and TP53 deletions or mutations were not detected
in samples from patients with monoclonal gammopathy of undeter-
mined significance, indicating that they may be drivers of progression to
myeloma. Data from this study show that monoclonal gammopathy of
undetermined significance is genetically similar to myeloma, however
overall genetic abnormalities are present at significantly lower levels in
monoclonal gammopathy of undetermined significant than in myeloma.
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ABSTRACT
Introduction
Monoclonal gammopathy of undetermined significance
(MGUS) is one of the most common pre-malignant condi-
tions and affects 3.2% of people over 50 years old, 5.3%
over 70 and 7.5% over the age of 85 years.1,2 MGUS is
characterized by a serum monoclonal protein <30 g/L,
<10% plasma cells in the bone marrow, and the absence
of end-organ damage (CRAB: hypercalcemia, renal insuf-
ficiency, anemia, or bone lesions). The MGUS progresses
to multiple myeloma (MM) in approximately 1% of
patients per year.3 Risk stratification models have been
proposed to assess risk of transformation using flow-
cytometry and serum free light chain.4-6
Advances in molecular genetics have opened up the pos-
sibility of identifying genetic events involved in malignant
transformation. Previous studies in MGUS have shown
that interphase fluorescence in situ hybridization can
detect known myeloma-specific chromosomal abnormali-
ties in MGUS patients. These chromosomal abnormalities
include IGH (14q32) translocations, RB1 (13q14) deletion,
1q gain and hyperdiploidy. These abnormalities are pres-
ent at lower frequencies in MGUS than in myeloma.7-9 The
potential prognostic significance of these abnormalities in
relation to the progression of MGUS has not been speci-
fied.10 It has been shown that the incidence of these vari-
ants increases from MGUS through smoldering MM
(SMM) to MM.11 Single nucleotide polymorphism (SNP)
arrays have also been used to detect copy-number alter-
ations (CNA) and these also increase in frequency from
MGUS (5/patient) through SMM (7.5/patient) to MM
(12/patient).12
Activation of proto-oncogenes, such as activation of
KRAS, NRAS, MYC and BRAF, has been less frequently
described in MGUS than in myeloma.13-15 In a previous
study,16 we described the exome mutation profile of four
MGUS patients which suggested that genomic complexity
increased from MGUS, through SMM, MM and plasma
cell leukemia. To understand the molecular pathogenesis
of MGUS and the role of genetic events in relation to
malignant transformation, more genome-wide studies in
MGUS datasets are required and in this study we per-
formed a comprehensive analysis of flow-sorted abnormal
plasma cells from 33 MGUS patients using whole exome
sequencing together with comparative genomic
hybridization (CGH)+SNP arrays.
Methods
Patients’ samples
Overall, 33 MGUS patients from centers in the Czech Republic
(Brno, Prague and Ostrava) were included in this study, which was
approved by the University Hospital Brno Ethical Committee,
after giving informed consent (Online Supplementary Table S1).
Bone marrow plasma cells were isolated from the mononuclear
cell fraction with a FACSAria (BD Biosciences, San Jose, CA, USA)
using CD138-PE, CD19-APC and CD56-FITC antibodies
(Beckman Coulter, Brea, CA, USA or Exbio, Prague, Czech
Republic) to obtain a phenotypically abnormal plasma cell popu-
lation (CD138+CD19-CD56+/-)17 with a median purity of 99.0%
(range, 93.6–99.9%). The flow-cytometry data before and after
plasma cell sorting are presented in Online Supplementary Figures S1
and S2. The median number of sorted cells was 57×103 (range,
15×103 – 480×103). Tumor DNA was isolated using a Gentra
Puregene Kit, amplified using the REPLI-g Midi Kit and purified
using the QIAamp DNA Mini Kit (all from Qiagen, Hilden,
Germany). Previous studies had demonstrated the suitability of
whole-genome-amplified DNA for array-CGH18-20 as well as next-
generation sequencing21-23 analysis. Control DNA was obtained
from peripheral white blood cells using a MagNA Pure System
(Hoffmann-La Roche, Basel, Switzerland). The quality and quan-
tity of DNA were measured by Qubit Fluorometer, Pico-green
(both from Thermo Fisher Scientific, Waltham, MA, USA) and/or
2200 Tapestation (Agilent Technologies, Santa Clara, CA, USA).
Comparative genomic hybridization and single
nucleotide polymorphism arrays
As previously described, 2–3 µg of whole-genome amplified
tumor DNA and Agilent Euro Male/Female (Agilent Technologies)
as control DNA were fragmented by AluI and RsaI (both from
Promega, Madison, WI, USA) restriction enzymes and fluores-
cently labeled with the BioPrime Total for Agilent aCGH Kit
(Thermo Fisher Scientific) or treated with the SureTag Complete
DNA Labeling Kit (Agilent Technologies).24 After purification of
labeled DNA, tumor and control DNA samples were combined
with COT Human DNA (Hoffmann-La Roche) and hybridization
mix (Oligo aCGH Hybridization Kit, Agilent Technologies), and
co-hybridized to SurePrint G3 CGH+SNP, 4x180K (Agilent
Technologies) arrays. After hybridization and washing, DNA
microarrays were scanned using a Microarray Scanner (Agilent
Technologies) with 3 mm resolution. Feature Extraction Software
12.0.2.2 (Agilent Technologies) was used for data extraction and
quality control evaluation. Genomic Workbench 7.0.4.0 (Agilent
Technologies) was used for CNA calling by the ADM-2 algorithm
with the following settings: ≥100 kb size, ≥0.2 fold change of log2
ratio, ≥5 consecutive probes. CNA were manually curated and the
default Database of Genomic Variants
(http://www.openhelix.com) for hg19 was used to eliminate com-
mon human population copy-number variants. The array data
supporting the results of this article are available at Gene
Expression Omnibus (GEO), National Center for Biotechnology
Information (NCBI) under the accession number GSE77979.
Exome sequencing
A previously published protocol was used for exome sequenc-
ing.25 A total of 200 ng DNA from peripheral blood and 3 mg
whole-genome amplified tumor DNA were fragmented by the
Covaris E-Series. Fragmented DNA was end-repaired, A-tailed
and adaptors ligated by the NEBNext DNA library prep master
mix set for Illumina (New England Biolabs, Ipswich, MA, USA).
Modified DNA was amplified by NEBNext High-fidelity poly-
merase chain reaction (PCR) master mix using either eight or four
PCR cycles in the case of control and tumor DNA, respectively. A
total of 750 ng amplified DNA was hybridized to custom-
designed RNA baits overnight (SureSelect Human All Exon V5,
Agilent Technologies; enriched for IGH, IGK, IGL and MYC
region capture). Captured DNA was indexed and amplified by
Herculase II fusion DNA polymerase (Agilent Technologies) for
eight PCR cycles. Samples were sequenced using a HiSeq 2000
(Illumina, San Diego, CA, USA) using four pooled samples per
lane and 76-bp paired-ends reads. Additional information about
data quality metrics and processing, somatic mutation calling and
non-negative matrix factorization is given in the Online
Supplementary Methods. Sequence read data for this study have
been submitted to the European Genome-Phenome Archive
(EGA) under accession number EGAS00001001658. The findings
from the 33 MGUS patients in this study were compared to data
from a cohort of 463 newly diagnosed MM (NDMM) patients
from a previous study (EGAS00001001147).26
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Basic statistical analysis
Data were analyzed using Statistica 12 software (StatSoft,
Prague, Czech Republic) and MedCalc 14.8.1 software (MedCalc
Software, Ostend, Belgium). Statistical tests were used as follows:
the Fisher exact test for categorical data, the Mann-Whitney U test
for continuous variables and Pearson correlation. P values ≤0.05
were considered statistically significant.
Results
Fewer copy-number changes are found in monoclonal
gammopathy of undetermined significance than
in multiple myeloma
Using high-density oligonucleotide CGH+SNP arrays,
CNA were detected in 60.6% (20/33) of MGUS patients in
comparison to 100% of MM patients, which were
described in our previous study.27 A summary plot of CNA
in the 33 MGUS cases is given in Online Supplementary
Figure S3 and frequencies of CNA at the chromosome-arm
level are listed in Online Supplementary Table S2. We found
123 CNA (42 losses and 81 gains). Although CGH+SNP
arrays with higher resolution were used in this study, the
median number of CNA per patient was only two (range,
0–15), fewer than the 16 (range, 1–52) found in the MM
dataset.27
Numerical CNA were present in 54.5% (18/33) of cases;
whole chromosome losses and whole chromosome gains
were found in 39.4% (13/33) and 30.3% (10/33) of cases,
respectively. Analogous to MM, we identified two distinct
subgroups within MGUS: non-hyperdiploid and hyper-
diploid. Non-hyperdiploidy was present in 72.7% (24/33)
of patients and we distinguished subtypes within this sub-
group as hypodiploid, pseudodiploid and diploid in 18.2%
(6/33), 9.1% (3/33) and 45.5% (15/33) of cases, respective-
ly. The most frequently lost chromosomes were 13
(27.3%, 9/33), X (18.2%, 6/33) and Y (12.1%, 4/33).
Hyperdiploidy was detected in 27.3% (9/33) of cases and
the most frequently gained chromosomes were 9 (27.3%,
9/33), 19 (27.3%, 9/33) and 3 (18.2%, 6/33). The median
number of chromosomes in hyperdiploid patients was 52
(range, 48–55). Interestingly, 88.9% (8/9) of hyperdiploid
patients also carried structural abnormalities in compari-
son to 29.2% (7/24) of non-hyperdiploid patients
(P=4.39×10-3). On the other hand, 54.2% (13/24) of non-
hyperdiploid patients had no CNA detected by CGH+SNP
arrays.
Structural abnormalities were seen in 45.5% (15/33) of
MGUS samples. These related to changes in complete
chromosome arms in 30.3% (10/33) of patients, mostly 1q
gain (27.3%, 9/33) and 16q loss (6.1%, 2/33). Smaller
interstitial changes were seen in 30.3% (10/33) of patients
with a median of 0 (range, 0–4) changes per patient with
a median size of 6.6 Mb (range, 0.1–88.8 Mb). We distin-
guished both interstitial and telomeric changes in 27.3%
(9/33) and 15.2% (5/33) of patients, respectively.
Recurrent deletions were detected at 1p and 6q, both in
6.1% (2/33) of samples, and at 14q in 12.1% (4/33) of
patients. Only one case of homozygous deletion was
found at 21q22.13, which did not include any known
tumor-associated genes (Online Supplementary Figure S4).
No deletions of 17p, a poor prognostic marker in MM and
the location of TP53, were detected.
Somatic mutations in monoclonal gammopathies
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Figure 1. Basic sequencing characteristics of the study. (A) Number of specific variants by nucleotide changes. (B) Comparison of specific variants by proportion of
nucleotide changes in MGUS and NDMM. (C) Number of variants by their effect on transcription. (D) Comparison of proportion of variants by type in MGUS and NDMM. 
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MYC translocations are not detected in monoclonal
gammopathy of undetermined significance
The exome capture was enriched for the IGH (14q32),
IGK (2p12), IGL (22q11.2) and MYC (8q24.21) loci,
enabling analysis of the most frequent chromosomal
translocations in MM.
We identified IGH translocations in 27.3% (9/33), con-
sisting of t(11;14) in 12.1% (4/33), t(4;14) in 9.1% (3/33),
t(14;16) in 3.0% (1/33) and t(14;20) in 3.0% (1/33) (Table
1). We defined the chromosome breakpoints on chromo-
somes 4, 11, 14, 16 and 20 (Online Supplementary Figure S5),
and the findings did not differ from those in MM.28 All
nine cases with an IGH translocation were non-hyper-
diploid. Two males with a t(11;14) as well as one male
with a t(14;20) did not have either numerical or structural
CNA and were diploid. Similarly, two females with a
t(11;14) only had loss of the X chromosome and were,
therefore, pseudodiploid. All three MGUS cases with a
t(4;14) had similar profiles with loss of chromosome 13
and loss of one gonosome (2 males with loss of Y and 1
female with loss of X) and were thus also hypodiploid (43,
44 and 44 chromosomes in a total). Furthermore, 66.7%
(2/3) of those with t(4;14) also had 1q gain. The patient
with a t(14;16) showed similarity to three cases of t(4;14)
with 1q gain and 13q loss.
In this cohort of 33 MGUS patients we did not find any
translocations involving MYC, even though they were
detected in 18.4% of NDMM using the same assay.29
There are fewer mutations in monoclonal gammopathy
of undetermined significance than in multiple 
myeloma
Acquired single nucleotide variants (SNV) were present
in all (33/33) MGUS patients with a median of 89 (range,
9–315) per patient, most frequently as transition rather
than transversion mutations, similarly to NDMM (Figure
1A,B). Exonic mutations and indels were found in a total
of 857 genes, with 70.4% (603/857) of these being non-
synonymous SNV (NS-SNV) (Figure 1C,D). These muta-
tions were present at a significantly lower level in MGUS
than in NDMM (P<10-4) (Figure 2; Online Supplementary
Table S3). However, 73.5% (443/603) of genes affected by
NS-SNV intersected with genes mutated in NDMM. NS-
SNV were present in 97.0% (32/33) of cases with a medi-
an of 19 (range, 0–70) NS-SNV per patient.
We did not find any significantly mutated genes, but
overall 35 genes were recurrently mutated and only three
genes were mutated in more than two cases: KLHL6 (mis-
sense mutations p.L90V p.L71Q and a c.-20T>A mutation
in the translation start site, a gene mutated in 13 patients
in NDMM), NPIPL2 (3 cases with missense mutation
p.H211R) and AKAP9 (missense mutations p.S3313N,
p.N2792S and p.R1973T; mutated in 6 NDMM).
In five MGUS cases we identified SNV in six genes
which were found to be significantly mutated in NDMM,
including KRAS (n=2), HIST1H1E (n=2) and NRAS, DIS3,
EGR1, LTB (all n=1) (Online Supplementary Table S4). When
a mutation was present in one of these genes the variant
allele frequency was not significantly different in MGUS
compared to NDMM (Online Supplementary Figure S6), but
was often lower. The only example of variant allele fre-
quency being equivalent in MGUS and NDMM was for
HIST1H1E, which was clonal, which may indicate that it
is a key driver.
We found one t(11;14) MGUS patient with two muta-
tions in CCND1 (p.K50T, p.E51D), which are associated
with a negative impact on survival in patients with MM.
We did not find any mutations in TP53, ATM, ATR or
ZFHX4, which have been identified as unfavorable factors
for patients’ survival and are involved in the DNA repair
pathway.
We tested for the presence of specific mutational signa-
tures,30 which we have previously shown to be related to
the pathological activity of specific cytidine deaminases of
the APOBEC family.29 The APOBEC mutational signature
was not found in this cohort of 33 MGUS patients, even
among those with a t(14;16) or t(14;20), possibly suggest-
ing that APOBEC activity does not drive disease progres-
sion in the MAF subgroup at the MGUS stage and that it
is, instead, acquired later in the development of MM
(Online Supplementary Figure S7). With regards to the
APOBEC signature, the frequency of mutations was high-
er in t(14;16) MM than in other subgroups.29 However, as
we had only one t(14;16) case in this series we could not
conclusively show a higher mutation rate in the MGUS
disease stage (Online Supplementary Figure S8).
Copy-number alterations are associated with increased
mutation rate
Some associations between mutations and structural
changes in NDMM have been described.26 In MGUS we
identified a patient with t(11;14) with two CCND1
(p.K50T, p.E51D) mutations, a case with a DIS3
(p.D488N) mutation and 13q loss and a case with an EGR1
mutation (p.M29L) with hyperdiploidy. Although, DIS3
mutations are associated with t(4;14) or t(14;16) in
NDMM, the MGUS case with a DIS3 mutation did not
have an IGH translocation.
An association between KRAS mutations and t(11;14)
has previously been documented, but neither of the two
MGUS patients with KRAS (p.Q61L and p.A146T) muta-
tions had a t(11;14); one had no IGH translocation and the
other had t(14;20). We also identified a patient with both
a KRAS (p.Q61L) and an NRAS (p.G13R) mutation which,
although not mutually exclusive, are negatively correlated
in NDMM. This patient was also hyperdiploid, which has
a positive correlation with NRAS mutations in NDMM,
and did not have deletion of 13q, which is negatively cor-
related with NRASmutations in NDMM. The presence of
more than one Ras pathway mutation in MM is associated
with intraclonal heterogeneity, where the Ras mutations
are present in different subclones. Here, the presence of
two Ras pathway mutations indicates that heterogeneity
can occur early in the disease process. Associations of spe-
A. Mikulasova et al.
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Table 1. Frequency of IGH translocations in monoclonal gammopathy
of undetermined significance compared to newly diagnosed multiple
myeloma.
Translocation MGUS (n = 33) NDMM (n = 463) P
Cases (%) Cases (%)
t(4;14) 3 (9.1%) 59 (12.7%) 0.79
t(6;14) 0 (0.0%) 5 (1.1%) 1.00
t(11;14) 4 (12.1%) 86 (18.6%) 0.48
t(14;16) 1 (3.0%) 17 (3.7%) 1.00
t(14;20) 1 (3.0%) 4 (0.9%) 0.29
cific SNV, CNA and clinical parameters are shown in
Online Supplementary Figure S9.
Interestingly, MGUS patients with CNA and/or IGH
translocations (n=23) had significantly higher numbers of
total SNV (P=8.17×10-5), exonic SNV (P=1.43×10-4), NS-SNV
(P=1.82×10-3) and synonymous SNV (S-SNV) (P=3.75×10-
4) in comparison to MGUS patients without any of these
changes (n=10) (Table 2). We also found a positive corre-
lation of increasing number of SNV and chromosomal
abnormalities (Figure 3).
Risk stratification of patients with monoclonal 
gammopathy of undetermined significance
Using a risk-stratification model,4 we divided 32 MGUS
patients into low risk (n=14), intermediate-low risk (n=9)
and intermediate-high risk (n=9). We found that the medi-
an number of CNA and/or IGH translocations increased
from low to intermediate-low and intermediate-high risk
groups: 0 (range, 0–10), 4 (range, 0–15) and 6 (range, 0–10),
respectively (Table 3). Gain of 1q [present in 7.1% (1/14),
11.1% (1/9) and 66.7% (6/9) patients, in the three risk
groups], as well as frequency of patients with at least one
structural CNA [14.3% (2/14), 55.6% (5/9) and 77.8%
(7/9), respectively], also increased with risk group. We did
not find a clear increase of SNV across the risk groups
(Table 3).
Presence of clonal abnormalities is associated with
higher risk of progression
MGUS cases were divided into six groups based on the
structure of intratumor heterogeneity (Figure 4): 86.7%
(13/15) of cases with at least one clonal CNA and NS-SNV
showed intermediate-low/high risk, while other groups
had small proportions of cases with higher risk of progres-
sion (29.4%, 5/17, P=0.002). This fact was caused by the
association of clonal alterations with non-IgG variant
(50.0%, 8/16; others: 11.8%, 2/17; P=0.03) and abnormal
serum kappa/lambda free light chain ratio (73.3%, 11/15;
others: 23.5%, 4/17; P=0.02). Chromosome abnormalities
were preceded by gene mutations as a total of 63.6%
(21/33) of cases showed at least one NS-SNV with a 10%
or higher proportion than any CNA present. There were
no examples with CNA but without NS-SNV, and no
cases with a CNA at a frequency of 10% or greater than
that of any NS-SNV.
Discussion
MGUS is considered a relatively benign disease, being
present in 3% of the population >50 years old but without
evidence of end-organ damage. However, recent evidence
indicates that nearly all cases of MM are preceded by an
MGUS phase.31,32 Analysis of the genomes of MGUS sam-
ples has revealed that the genetic composition in this dis-
order is strikingly similar to that in MM, with the presence
of IGH translocations, hyperdiploidy, gain 1q, and dele-
tion 1p. However, these abnormalities are, in general,
present at lower frequencies in the MGUS population.12
These abnormalities have been characterized in MGUS
using classical cytogenetics and fluorescence in situ
hybridization, as well as mapping arrays to detect changes
Somatic mutations in monoclonal gammopathies
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Table 2. Relationship between the number of single nucleotide variants and the presence of chromosomal abnormalities. 
SNV category At least one chromosomal No chromosomal P
abnormality (n = 23) abnormality (n = 10)
Median (range) Median (range)
Total SNV 102 (32–315) 29 (9–92) 8.17×10-5
Exonic SNV 30 (5–111) 11 (2–23) 1.43×10-4
NS-SNV 23 (4–70) 9 (0–24) 1.82×10-3
S-SNV 11 (1–42) 3 (1–6) 3.75×10-4
Chromosomal abnormalities include CNA tested by CGH+SNP arrays and IGH translocations defined by exome sequencing.
Figure 2. Number of single nucleotide variants in 33
patients with monoclonal gammopathy of undeter-
mined significance compared to 463 patients  with
newly diagnose multiple myeloma.
at a higher resolution.11,12,33,34 However, exome sequencing
in MGUS has only been performed in a handful of
patients16 so the dataset has been too small to make mean-
ingful conclusions. Here, we report the first comprehen-
sive analysis of genome-wide genetic changes in 33
MGUS samples in which flow-cytometry-separated phe-
notypically abnormal plasma cells were analyzed, to
exclude contamination by phenotypically normal plasma
cells, followed by array CGH and exome sequencing.
We found that the frequency of chromosomal gains and
losses, including hyperdiploidy, gain 1q, and del(13q), is
lower in MGUS than in MM. Hyperdiploidy is considered
as a primary myeloma lesion; however it has prognostic
potential in asymptomatic stages as has been shown in
SMM.35 The frequency of MGUS samples with CNA is
60.6%. the minimum size of the alterations is 100 kb and
there are a median of two CNA per case. These numbers
are lower compared to those for cases of MM which we
previously analyzed.27 Homozygous deletion affecting
genes such as FAF1/CDKN2C, BIRC2/BIRC3, RB1,
TRAF3/AMN and CYLD are common in MM,27,36 but they
were not present in MGUS.
The number of SNV in the samples was also significant-
ly lower in MGUS than in NDMM; exonic, non-synony-
mous, synonymous and total SNV were all found at a
lower frequency. Of the variants, there were no signifi-
cantly mutated genes. However, there were variants pres-
ent which were significant in our previous NDMM
dataset, including KRAS, NRAS, HIST1H1E, DIS3, EGR1
and LTB.
A. Mikulasova et al.
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Table 3. Number of chromosomal abnormalities and single nucleotide variants per case across the monoclonal gammopathy of undetermined
significance risk groups. 
Low risk Int.-low risk Int.-high risk P for low P for low P for int.low
(n = 14) (n = 9) (n = 9) vs. vs. vs.
Median (range) Median (range) Median (range) int.-low int-high int.-high
Chromosomal 0 (0–10) 4 (0–15) 6 (0–10) 1.90×10-2 3.44×10-2 0.86
abnormalities
Total SNV 58.5 (13–128) 112 (44–315) 89 (9–146) 8.12×10-3 0.15 0.12
Exonic SNV 16.5 (2–32) 33 (5–111) 29 (3–38) 1.17×10-2 1.96×10-2 0.31
NS-SNV 13 (0–29) 24 (4–70) 21 (1–30) 2.12×10-2 0.11 0.20
S-SNV 3.5 (1–12) 11 (1–42) 9 (2–14) 5.31×10-3 7.05×10-3 0.23
Chromosomal abnormalities include CNA tested by CGH+SNP arrays and IGH translocations defined by exome sequencing. MGUS groups are defined by a model based on
risk factors as follows: non-IgG isotype of serum monoclonal protein, ≥15 g/L of serum monoclonal protein and abnormal serum kappa/lambda free light chain ratio (<0.26 or
>1.65).
Figure 3. Correlation analysis of increasing number of chromosome abnormalities and single nucleotide variants per sample in 33 patients with monoclonal gam-
mopathy of undetermined significance. Chromosome abnormalities (CHA) include CNA tested by CGH+SNP arrays and IGH translocations defined by exome
sequencing. (A) CHA and total SNV. (B) CHA and exonic SNV. (C) CHA and NS-SNV. (D) CHA and S-SNV.
A
C D
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Insights into the molecular timing of genetic events can
be gained by analyses of known MM-specific events in
MGUS cases. NRAS mutations have been detected in
MGUS previously, but KRAS mutations have not previ-
ously been found in MGUS and were implicated in the
transition from MGUS to MM.15 Previously, in a limited
number of MGUS samples (n=20), one NRAS mutation
and no KRASmutations were detected, whereas in our 33
MGUS cases we found one patient with a clonal KRAS
mutation and one with both subclonal KRAS and NRAS
mutations. Neither of these two patients with RAS muta-
tions had progressed to MM after a follow-up of 50 and 67
months. Our results confirmed that the frequency of RAS
mutations in MGUS is significantly lower than in MM,
but also showed that activation of this pathway does not
necessarily mark the onset of disease progression.
Interestingly, the presence of both a KRAS and NRAS
mutation in one patient indicates early diversification and
heterogeneity in this pre-malignant condition.
Another candidate for association with disease progres-
sion is del(17p) and/or mutation of the TP53 gene.37 We
detected neither in this MGUS dataset, but they account
for up to 11% of mutations in NDMM. Mutations in ATM
and ATRwere also not detected in MGUS but their preva-
lence in NDMM is low (<2% each) so would not have
been expected in this dataset. MYC translocations were
not detected in MGUS by our targeted capture of 2 Mb
surrounding MYC, which has detected translocations in
18% of NDMM.26 This change at the MYC locus is consis-
tent with data from gene expression analyses showing
that MYC over-expression occurs in two-thirds of MM
cases, but uncommonly in MGUS.38-41 RAS mutations,
TP53 alterations and MYC translocations are all known
oncogenic drivers and are likely candidates for being
involved in disease progression but not initiation of the
myeloma propagating cell. Moreover, del(17p)35,42 and
MYC rearrangement43 have been observed as risk progres-
sion factors in SMM.
We have previously identified mutations in CCND1,
associated with the t(11;14), which have a negative impact
on survival. In our MGUS dataset there were four t(11;14)
samples, of which one had two missense mutations in
CCND1. This is consistent with NDMM, given the low
numbers of t(11;14) samples, perhaps implying that there
is not a link with disease progression. The frequency of
IGH translocations detected by exome sequencing did not
differ significantly from that found in previous fluores-
cence in situ hybridization-based studies, however a signif-
icantly lower t(4;14) and higher t(14;20) frequency in
MGUS compared to MM was not seen due to the limited
number of MGUS cases.44,45
In conclusion, MGUS is better defined by the genomic
abnormalities that are absent than by the ones that are
present. We show that some MM-specific structural and
SNV are present in MGUS, but the overall prevalence of
such lesions is significantly lower than in MM. Structural
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Figure 4. Intratumor heterogeneity in monoclonal gammopathy of undetermined significance. Each column shows the proportion (vertical axis) of NS-SNV (red
points) and CNA (blue points) in each MGUS patient. The black line represents a frequency distribution of somatic changes. The presence of myeloma-significantly
mutated genes, 1q gain and chromosome 13 loss is highlighted by dark colors. Red stars mark cases with at least one NS-SNV with 10% or higher proportion than
any CNA present. Patients are divided into groups by clonal features of somatic alterations: (A) Subclonal NS-SNV and no CNA. (B) Clonal/subclonal NS-SNV and no
CNA. (C) Subclonal NS-SNV and subclonal CNA. (D) Clonal/subclonal NS-SNV and subclonal CNA. (E) Clonal/sublonal NS-SNV and clonal/subclonal CNA. (F)
Clonal/subclonal NS-SNV and clonal CNA. Only NS-SNV with a minimum 10% proportion are displayed. One of 33 patients is not shown as no NS-SNV and CNA were
detected.
A B C D
E F
changes such as gain 1q and del(1p) are present in MGUS,
at relatively high frequencies, implying they may lay the
ground for progression but are not key drivers of progres-
sion. Key oncogenic drivers, namely TP53 deletion and/or
mutation and MYC translocations, are noticeably absent
from this MGUS dataset and are, therefore, better candi-
dates for the onset of disease progression.
Here, we show that samples with clonal copy-number
changes and mutations are associated with non-IgG heavy
chain isotype and abnormal light chain ratio, which are
known markers of high-risk MGUS. The clonal complexi-
ty of these samples (Figure 4E,F) is in stark contrast to the
relative simplicity of those associated with a low risk of
disease progression (Figure 4A-D). Follow up of these
cases over time and analysis of progressive samples from
MGUS, through SMM to MM will provide interesting
insights into the evolutionary mechanisms of selection for
aggressive malignant clones containing key driver events.
These observations are consistent with a Darwinian
model of myeloma evolution whereby genomic abnor-
malities are accumulated as disease progresses. We
hypothesize that transformation from MGUS to MM is
due to the acquisition of critical driver gene variants which
alters the behavior of a myeloma propagating cell, which
is accompanied by a wave of clonal expansion and clonal
dominance resulting in crucial differences in clinical
behavior.
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